Open Access

Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non‑alcoholic fatty liver disease mouse model

  • Authors:
    • Yulei Lu
    • Youzhi Lin
    • Xiaoqing Huang
    • Shengming Wu
    • Jian Wei
    • Chun Yang
  • View Affiliations

  • Published online on: April 1, 2019     https://doi.org/10.3892/ijmm.2019.4154
  • Pages: 2398-2408
  • Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Oxaliplatin (OXA)‑based chemotherapy is widely used in the treatment of gastrointestinal tumors; however, it is associated with chemotherapy‑associated liver injury. Whether OXA induces liver injury and aggravates the already existing hepatic oxidative stress, inflammation and fibrosis in non‑alcoholic fatty liver disease (NAFLD), and whether these effects can be alleviated by reduced glutathione (GSH) treatment, remains unclear. In the present study, OXA induced acute liver injury in NAFLD mice. Moreover, OXA increased the levels of reactive oxygen species (ROS) and malondialdehyde (MDA) and decreased the levels of superoxide dismutase and GSH peroxidase in the livers of NAFLD mice. OXA also induced the upregulation of hepatic inflammatory cytokines, such as tumor necrosis factor (TNF)‑α, interferon (IFN)‑γ and interleukin (IL)‑17, in NAFLD mice. Furthermore, collagen fiber deposition in liver tissues was increased and the expression of transforming growth factor (TGF)‑β, α‑smooth muscle actin (SMA) and tissue inhibitor of metallopeptidase (TIMP)‑1 was upregulated in the livers of OXA‑treated NAFLD mice. Treatment with exogenous GSH alleviated OXA‑induced acute liver injury in NAFLD mice, and significantly reduced the levels of ROS, MDA and TNF‑α. However, GSH treatment did not inhibit collagen fiber deposition, although it reduced the levels of IFN‑γ, IL‑17, TGF‑β, α‑SMA and TIMP‑1 in the livers of OXA‑treated NAFLD mice. In conclusion, OXA chemotherapy may induce acute liver injury and aggravate the existing hepatic oxidative stress, inflammation and fibrosis in NAFLD. Treatment of NAFLD mice with exogenous GSH alleviated OXA‑induced liver injury, possibly by ameliorating OXA‑aggravated hepatic oxidative stress and inflammation; it did not, however, attenuate OXA‑aggravated liver fibrosis.

References

1 

Riddell IA: Cisplatin and oxaliplatin: Our current understanding of their actions. Met Ions Life Sci. 18:2018.PubMed/NCBI

2 

Formica V, Zaniboni A, Loupakis F and Roselli M: Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice. Int J Cancer. 143:2342–2350. 2018. View Article : Google Scholar : PubMed/NCBI

3 

Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, et al: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 15:460–466. 2004. View Article : Google Scholar : PubMed/NCBI

4 

Duwe G, Knitter S, Pesthy S, Beierle AS, Bahra M, Schmelzle M, Schmuck RB, Lohneis P, Raschzok N, Öllinger R, et al: Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. Eur J Surg Oncol. 43:1668–1681. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, White SA and Mann DA: Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol. 59:318–326. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Chun YS, Laurent A, Maru D and Vauthey JN: Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 10:278–286. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Lin Y, Li Y, Hu X, Liu Z, Chen J, Lu Y, Liu J, Liao S, Zhang Y, Liang R, et al: The hepatoprotective role of reduced glutathione and its underlying mechanism in oxaliplatin-induced acute liver injury. Oncol Lett. 15:2266–2272. 2018.PubMed/NCBI

8 

Issa D, Patel V and Sanyal AJ: Future therapy for non-alcoholic fatty liver disease. Liver Int. 38(Suppl 1): S56–S63. 2018. View Article : Google Scholar

9 

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N and Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 37:917–923. 2003. View Article : Google Scholar : PubMed/NCBI

10 

Fiorucci S, Biagioli M and Distrutti E: Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol Res. 134:289–298. 2018. View Article : Google Scholar : PubMed/NCBI

11 

Martinez MA, Vuppalanchi R, Fontana RJ, Stolz A, Kleiner DE, Hayashi PH, Gu J, Hoofnagle JH and Chalasani N: Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol. 13:369–376e3. 2015. View Article : Google Scholar

12 

Lu Y, Wang X, Yan W, Wang H, Wang M, Wu D, Zhu L, Luo X and Ning Q: Liver TCRγδ(+) CD3(+) CD4(−) CD8(−) T cells contribute to murine hepatitis virus strain 3-induced hepatic injury through a TNF-α-dependent pathway. Mol Immunol. 52:229–236. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, Federico A and Persico M: Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018:95476132018. View Article : Google Scholar : PubMed/NCBI

14 

Green CJ, Parry SA, Gunn PJ, Ceresa CDL, Rosqvist F, Piché ME and Hodson L: Studying non-alcoholic fatty liver disease: The ins and outs of in vivo, ex vivo and in vitro human models. Horm Mol Biol Clin Investig. Aug 11–2018.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI

15 

Koek GH, Liedorp PR and Bast A: The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta. 412:1297–1305. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Chen Y, Dong H, Thompson DC, Shertzer HG, Nebert DW and Vasiliou V: Glutathione defense mechanism in liver injury: Insights from animal models. Food Chem Toxicol. 60:38–44. 2013. View Article : Google Scholar : PubMed/NCBI

17 

Del Campo JA, Gallego P and Grande L: Role of inflammatory response in liver diseases: Therapeutic strategies. World J Hepatol. 10:1–7. 2018. View Article : Google Scholar : PubMed/NCBI

18 

Gao B: Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. J Gastroenterol Hepatol. 27(Suppl 2): S89–S93. 2012. View Article : Google Scholar

19 

Yano A, Higuchi S, Tsuneyama K, Fukami T, Nakajima M and Yokoi T: Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. Toxicology. 293:107–114. 2012. View Article : Google Scholar : PubMed/NCBI

20 

Rutherford A and Chung RT: Acute liver failure: Mechanisms of hepatocyte injury and regeneration. Semin Liver Dis. 28:167–174. 2008. View Article : Google Scholar : PubMed/NCBI

21 

Mittal M, Siddiqui MR, Tran K, Reddy SP and Malik AB: Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 20:1126–1167. 2014. View Article : Google Scholar :

22 

Zhang X, Zhang JH, Chen XY, Hu QH, Wang MX, Jin R, Zhang QY, Wang W, Wang R, Kang LL, et al: Reactive oxygen species-induced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation. Antioxid Redox Signal. 22:848–870. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Deng Y, Ren X, Yang L, Lin Y and Wu X: A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell. 115:61–70. 2003. View Article : Google Scholar : PubMed/NCBI

24 

van Wetering S, van Buul JD, Quik S, Mul FP, Anthony EC, ten Klooster JP, Collard JG and Hordijk PL: Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J Cell Sci. 115:1837–1846. 2002.PubMed/NCBI

25 

Fabregat I and Caballero-Diaz D: Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis. Front Oncol. 8:3572018. View Article : Google Scholar

26 

Kisseleva T and Brenner DA: Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol. 22(Suppl 1): S73–S78. 2007. View Article : Google Scholar : PubMed/NCBI

27 

Lin W, Tsai WL, Shao RX, Wu G, Peng LF, Barlow LL, Chung WJ, Zhang L, Zhao H, Jang JY and Chung RT: Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology. 138:2509–2518. 2518.e12010. View Article : Google Scholar : PubMed/NCBI

28 

Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, Wang X, Ryffel B and Sun B: IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol. 191:1835–1844. 2013. View Article : Google Scholar : PubMed/NCBI

29 

Yuan L and Kaplowitz N: Glutathione in liver diseases and hepatotoxicity. Mol Aspects Med. 30:29–41. 2009. View Article : Google Scholar

30 

Wang J, Chen Y, Gao N, Wang Y, Tian Y, Wu J, Zhang J, Zhu J, Fan D and An J: Inhibitory effect of glutathione on oxidative liver injury induced by dengue virus serotype 2 infections in mice. PLoS One. 8:e554072013. View Article : Google Scholar : PubMed/NCBI

31 

Peter C, Braidy N, Zarka M, Welch J and Bridge W: Therapeutic approaches to modulating glutathione levels as a pharmacological strategy in Alzheimer's disease. Curr Alzheimer Res. 12:298–313. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Gross CL, Giles KC and Smith WJ: L-oxothiazolidine 4-carboxylate pretreatment of isolated human peripheral blood lymphocytes reduces sulfur mustard cytotoxicity. Cell Biol Toxicol. 13:167–173. 1997. View Article : Google Scholar : PubMed/NCBI

33 

Zou X, Wang Y, Peng C, Wang B, Niu Z, Li Z and Niu J: Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin-induced model of liver injury. Int J Mol Med. 42:2020–2030. 2018.PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 43 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Lu, Y., Lin, Y., Huang, X., Wu, S., Wei, J., & Yang, C. (2019). Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non‑alcoholic fatty liver disease mouse model. International Journal of Molecular Medicine, 43, 2398-2408. https://doi.org/10.3892/ijmm.2019.4154
MLA
Lu, Y., Lin, Y., Huang, X., Wu, S., Wei, J., Yang, C."Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non‑alcoholic fatty liver disease mouse model". International Journal of Molecular Medicine 43.6 (2019): 2398-2408.
Chicago
Lu, Y., Lin, Y., Huang, X., Wu, S., Wei, J., Yang, C."Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non‑alcoholic fatty liver disease mouse model". International Journal of Molecular Medicine 43, no. 6 (2019): 2398-2408. https://doi.org/10.3892/ijmm.2019.4154